INTRODUCTION {#S1}
============

Recently identified types of immune effector cells, termed innate lymphoid cells (ILCs), have been found in mouse and human tissues, including lung, gut, skin, and adipose tissue (reviewed in ref.^[@R1]^). Despite lacking antigen receptors, these cells nevertheless display a wide range of effector functions, in many cases mirroring those seen in T helper cell subsets. ILCs likely provide a more rapid response to certain pathogens than provided by the adaptive immune system, as well as playing a role in modulating subsequent innate and adaptive immune responses^[@R1]^. In addition, ILCs can play a reparative role in response to tissue injury, where cytokine secretion by infected or damaged tissue, rather than foreign antigen production, is the activating signal^[@R2]^.

Like T helper cell subsets, ILCs are classified based on their effector cytokine secretion profile and development of each subset is associated with key transcriptional regulators. T-bet-dependent group 1 ILCs (ILC1s) are IL-12 responsive, secrete IFN-γ and TNF, and are involved in controlling intracellular infections^[@R3]^. Group 2 ILCs (ILC2s) secrete IL-5 and IL-13 upon stimulation with IL-33 and, like T~H~2, are GATA-3 dependent^[@R4]^. However, GATA-3 also plays an obligatory role in development of other ILC lineages^[@R5]^. In addition, ILC2 development is dependent on transcriptional regulators RORα and TCF-1^[@R6],[@R7]^. Activation of ILC2s can in turn regulate eosinophils^[@R8]^, alternatively activated macrophages^[@R9]^, as well as T~H~2 cells in the context of allergen-induced airway inflammation^[@R10]^. RORγt-dependent group 3 ILCs (ILC3) include fetal lymphoid tissue inducer cells (LTi), which are required for lymph node organogenesis^[@R11]^, and CD4^+^ LTi-like cells found in the adult^[@R12]^. Other ILC3s express the natural cytotoxicity receptor (NKp46^+^)^[@R13]^, are dependent on TCF-1 for development^[@R14]^ and are involved in maintaining intestinal homeostasis^[@R15]^. ILC3s secrete IL-22 and IL-17A when activated with IL-23^[@R16]^ and granulocyte-macrophage colony-stimulating factor in response to IL-1β production by macrophages^[@R15]^. Splenic ILC3s have been identified in both human and mouse, and provide marginal zone B cell help through T cell-independent mechanisms^[@R17]^.

All ILCs arise from common lymphoid progenitors (CLP) in BM and fetal liver through a Notch-^[@R6],[@R18]--[@R20]^ and Id2-dependent process^[@R21],[@R22]^. PLZF, a transcriptional regulator also implicated in NKT cell function^[@R23]^, marks a subset of α~4~β~7~^+^ ILC lineage-specific progenitors that can give rise to all ILCs, except LTi and cNK^[@R24]^. These data suggested the presence of an earlier common ILC progenitor. Indeed, Id2-reporter mice were used to identify a cell population termed the common progenitor to all helper-like ILCs (CHILP), which give rise to multiple ILC lineages, including LTi, and contain a subpopulation of PLZF^hi^ cells^[@R3]^. Neither the PLZF^hi^ nor CHILP populations can differentiate into the cNK lineage. The basic leucine zipper transcription factor NFIL3 was shown to be required for the development of cNK, ILC1s, ILC2s and ILC3s^[@R25]--[@R27]^, and in its absence, the Lin^−^α~4~β~7~^+^CD127^+^c-Kit^lo^Sca-1^lo^Flt3^−^ progenitor population, including a minor subset of CXCR6^+^ cells, failed to develop ^[@R27],[@R28]^. However, the relationship between these cells and CHILP is unclear because Id2 was not used as an identifying marker for the CXCR6^+^ cell population^[@R27]^. More restricted ILC1 (ILC1p) and ILC2 (ILC2p) precursors in the BM have also been identified^[@R4]^.

TOX (thymocyte selection-associated high-mobility group box protein) is a member of the HMG-box superfamily of DNA binding factors^[@R29],[@R30]^ and is required for development of T cell subsets including CD4^+^ T, regulatory T and natural killer T (NKT) cells, as well as cNK and fetal LTi cells^[@R31]--[@R33]^. As a consequence of the loss of LTi, TOX-deficient (*Tox*^−/−^) mice lack lymph nodes. Based on some phenotypic overlap between Id2 and TOX deficiency, we investigated whether TOX, like Id2, might also play a broader role in ILC development. Here we show coincident expression of TOX and Id2 in CHILP. Moreover, intrinsic TOX deficiency resulted in low ILC1, ILC2, and splenic ILC3 numbers, due to the inhibition of Lin^−^α~4~β~7~^+^CD127^+^CD25^−^Flt3^−^ progenitor development. Whole transcriptome analysis suggests loss of TOX leads to a post CLP and pre CHILP block at a potential transitional stage of ILC progenitor cell development. Moreover, induction of key ILC transcriptional regulators and cell survival mediators was diminished in the absence of TOX, and evidence suggests a failure to fully activate a Notch-mediated gene program. *In vitro* modeling demonstrated an early cell-intrinsic defect not only in expansion and/or survival of progenitors in the absence of TOX, but also failure to upregulate a number of key factors for ILC development. Together, these data support a role for TOX as an essential factor in ILC lineage specification.

RESULTS {#S2}
=======

CHILP co-express *Tox* and *Id2* {#S3}
--------------------------------

To assess expression of TOX in the development of ILCs, we generated a tandem dimer Tomato (TOM) reporter strain of mouse, *Tox^TOM^* ([Fig. 1a](#F1){ref-type="fig"}). As all ILC development is Id2-dependent^[@R21]^, we additionally bred *Tox*^TOM^ mice to *Id2*^GFP^ reporter animals^[@R34]^. *Tox* is upregulated during the NK cell precursor (NKp) to immature NK cell (*i*NK) transition in BM, with subsequent down regulation in mature NK cells (mNK)^[@R32]^. *Tox*^TOM^*Id2*^GFP^ mice recapitulated this expression pattern ([Fig. 1b](#F1){ref-type="fig"}). Fewer mNK cells expressed TOM, consistent with *Tox* mRNA in this cell population^[@R32]^, while GFP remained high ([Fig. 1b](#F1){ref-type="fig"}). Together, these data support the utility of the *Tox* reporter strain to study ILC development.

Adult ILC subsets develop from CLP^[@R6],[@R19],[@R28]^ (cell population definitions as in [Supplementary Table 1](#SD2){ref-type="supplementary-material"}). There was little reporter expression in *Tox*^TOM^*Id2*^GFP^ CLP ([Fig. 1c](#F1){ref-type="fig"}). Among Lin^−^α~4~β~7~^+^ CD127^+^CD25^−^ cells, \~80% were GFP^+^, fitting the phenotypic definition of CHILP ([Fig. 1d](#F1){ref-type="fig"}). These cells were also TOM^+^ ([Fig. 1d](#F1){ref-type="fig"}). However, a subpopulation of this α~4~β~7~^+^ subset did not express *Tox* or *Id2* reporters. Lin^−^α~4~β~7~^+^ CD127^+^CD25^+^ cells, containing ILC2p^[@R4]^, also expressed GFP and TOM ([Fig. 1d](#F1){ref-type="fig"}).

Mature lung ILC2s (defined as in [Supplementary Fig. 1a](#SD1){ref-type="supplementary-material"}) expressed TOM in a heterogeneous pattern ([Supplementary Fig. 1b, c](#SD1){ref-type="supplementary-material"}), as well as *Tox* mRNA ([Fig. 1f](#F1){ref-type="fig"}). A proportion of NKT cells ([Supplementary Fig. 1d](#SD1){ref-type="supplementary-material"}) also expressed TOM, consistent with the known role for TOX in NKT cell development^[@R31]^, although with differing pattern of reporter expression when compared to ILC2s ([Supplementary Fig. 1b](#SD1){ref-type="supplementary-material"}). Unlike *Gata3*, expressed by ILC2s and T~H~2 cells^[@R4],[@R35]^, *Tox* was solely expressed in ILC2s ([Fig. 1f](#F1){ref-type="fig"}). Neither *Gata3* nor *Tox* was expressed by B cells ([Fig. 1f](#F1){ref-type="fig"}), as expected^[@R31]^.

The small intestine lamina propria (LP) contains multiple ILC subsets^[@R1]^. All ILC subtypes in LP expressed TOM ([Fig. 1g, h](#F1){ref-type="fig"}). ILC3s are also present in spleen^[@R17]^ and TOM was expressed in a proportion of all splenic ILC3 subtypes ([Fig 1i, j](#F1){ref-type="fig"}). Together with previous results, these data confirm expression of *Tox* in all known ILC subsets.

Common ILC progenitor development requires TOX {#S4}
----------------------------------------------

*Tox^−/−^* animals had normal numbers of CLP as compared to WT littermates ([Fig. 2a--c](#F2){ref-type="fig"}). In contrast, there was a severe loss of Lin^−^α~4~β~7~^+^CD127^+^Flt3^−^ cells in the absence of TOX ([Supplementary Fig. 2a--c](#SD1){ref-type="supplementary-material"}). In WT, a majority of Lin^−^α~4~β~7~^+^CD127^+^ cells expressed CD25 and these were largely absent in *Tox*^−/−^ mice ([Fig. 2e](#F2){ref-type="fig"}). Strikingly, the number of Lin^−^α~4~β~7~^+^CD127^+^CD25^−^ cells, the majority of which are CHILP ([Fig. 1d](#F1){ref-type="fig"})^[@R3],[@R28]^, was reduced to approximately 20% of their WT counterparts in *Tox^−/−^* animals ([Fig. 2d--f](#F2){ref-type="fig"}). A heterogeneous population of Lin^−^CD45^+^NK1.1^+^NKp46^+^ cells consisting of cNK (CD27^−^CD127^−^), ILC1s (CD27^+^CD127^+^), ILC3s (CD27^−^CD127^+^), and ILC1 restricted progenitors (ILC1p) can be found in BM^[@R3]^. In the absence of TOX, this cell population was lost ([Fig. 2g, h, i](#F2){ref-type="fig"}).

ILC2s develop from CLP thorough a lineage-committed progenitor (ILC2p) ^[@R4]^. ILC2p also expressed TOM ([Fig. 1d](#F1){ref-type="fig"}) and were absent from *Tox^−/−^* BM ([Fig. 2j--l](#F2){ref-type="fig"}). ILC2p are IL-33R^+^ and can be expanded *in vivo* upon injection of IL-33^[@R4]^. IL-33 led to a modest increase in ILC2p in the BM of *Tox^−/−^* animals, but not to the level seen in WT mice ([Supplementary Fig. 2d--f](#SD1){ref-type="supplementary-material"}).

TOX-dependent development of ILC-committed progenitors would predict failure to develop mature ILC in *Tox*^−/−^ mice. Both cNK cells and ILC1s were present in lung of WT but not *Tox^−/−^* mice ([Fig 3a, b, c, d](#F3){ref-type="fig"}). NK1.1^+^NKp46^+^ cells were lost from *Tox^−/−^* animals in the colon ([Fig. 3e](#F3){ref-type="fig"}) and small intestine ([Fig. 3g, f, h](#F3){ref-type="fig"}). Intracellular staining for lineage-determining transcription factors in the colon ([Supplementary Fig. 3a](#SD1){ref-type="supplementary-material"}) and small intestine ([Supplementary Fig. 3b](#SD1){ref-type="supplementary-material"}) indicated that these cells consisted of cNK, ILC1s, and a minor population of ILC3s.

ILC2s in the lung were significantly reduced in *Tox^−/−^* mice ([Fig. 3i--k](#F3){ref-type="fig"}). As is also true for T cell development^[@R33]^, heterozygous loss of *Tox* had no effect on the presence of ILC2s ([Fig. 3j, k](#F3){ref-type="fig"}). WT ILC2s expanded greatly in lung of IL-33-treated mice ([Fig. 3l--n](#F3){ref-type="fig"}). However, only minimal expansion of ILC2s was observed in lungs of *Tox^−/−^* mice, and cell recovery was poor, even compared to WT untreated animals ([Fig. 3l--n](#F3){ref-type="fig"}). Expanded ILC2s from *Tox^−/−^* animals also expressed less of the IL-33R ST2 subunit, possibly indicative of abnormal development ([Fig. 3o](#F3){ref-type="fig"}).

Splenic ILC3s contained both CD4^−^ and CD4^+^ populations, and both were significantly diminished in *Tox^−/−^* animals ([Fig. 3q, r](#F3){ref-type="fig"}). Similarly, splenic NKp46^+^ and NKp46^−^ ILC3s were significantly decreased in the absence of TOX ([Supplementary Fig. 4a, b](#SD1){ref-type="supplementary-material"}). LP ILC3s are heterogeneous, containing fetal derived LTi-like cells and postnatal NKp46^−^ (both T-bet^+^ and T-bet^−^) and NKp46^+^T-bet^+^ cells^[@R36]^. Even in the same animals where splenic ILC3s were lost, there was no reduction in the frequency of total ILC3s in *Tox^−/−^* LP, or subpopulations defined by NKp46 or T-bet, while ILC2s were absent ([Supplementary Fig. 4a, c, d](#SD1){ref-type="supplementary-material"}). Moreover, the yield of NKp46^+^ ILC3s was significantly increased in *Tox^−/−^* LP preparations ([Supplementary Fig. 4e](#SD1){ref-type="supplementary-material"}). NKp46^−^ ILC3s were also isolated in greater numbers from mutant compared to WT animals, although this difference did not reach statistical significance ([Supplementary Fig. 4e](#SD1){ref-type="supplementary-material"}). In contrast to WT, the *Tox^−/−^* NKp46^−^T-bet^−^ subset did not contain CCR6^hi^ cells ([Supplementary Fig. 4e](#SD1){ref-type="supplementary-material"}), consistent with loss of the fetal LTi-like subpopulation^[@R36]^.

Loss of TOX results in a near complete block in development of CD4^+^ T cells in the thymus^[@R31]^ ([Supplementary Fig. 4f](#SD1){ref-type="supplementary-material"}). Nevertheless, Lin^+^CD45^+^Thy-1^+^CD4^+^ cells were observed in the LP of these animals and the majority was RORγt^+^ ([Supplementary Fig. 4f](#SD1){ref-type="supplementary-material"}). Moreover, \>80% of the total Lin^+^CD45^+^Thy-1^+^ cell population was RORγt^+^ ([Supplementary Fig. 4f](#SD1){ref-type="supplementary-material"}). This is consistent with an inflammatory environment in the *Tox^−/−^* small intestine, potentially caused by loss of T regulatory cells^[@R31]^. Whether TOX-independent lineages of ILC3s exist or, alternatively, if the perturbed immune system in *Tox^−/−^* animals leads to expansion of minor populations of both CD4^+^ T cells and ILC3s remains to be determined.

To verify that loss of TOX inhibited ILC development by a cell-intrinsic mechanism, BM chimeras were generated by injecting WT and *Tox^−/−^*CLP at equal ratios into NSG mice, which lack all T cells, B cells and ILCs. Of the donor-derived Lin^−^α~4~β~7~^+^CD127^+^ progenitors that developed, greater than 90% were derived from WT CLP ([Fig. 4a](#F4){ref-type="fig"}). Similarly, the vast majority of donor-derived ILC1s ([Fig. 4b](#F4){ref-type="fig"}) and ILC2s ([Fig. 4c](#F4){ref-type="fig"}) in the lung, and splenic ILC3s ([Fig. 4d](#F4){ref-type="fig"}) were derived from WT CLP. [Figure 4e](#F4){ref-type="fig"} presents compiled data. In contrast, we did not observe a WT bias during thymocyte development (data not shown). Thus, all subtypes of ILCs, including the common progenitor, are intrinsically TOX dependent.

Molecular dissection of TOX-mediated ILC progenitor differentiation {#S5}
-------------------------------------------------------------------

Lin^−^α~4~β~7~^+^CD127^+^CD25^−^Flt3^−^ BM cells, which include the earliest known ILC progenitors^[@R3],[@R24]^, are severely reduced in *Tox^−/−^* mice, although not entirely absent ([Fig. 2f](#F2){ref-type="fig"} and [Supplementary Fig. 2a--c](#SD1){ref-type="supplementary-material"}). We took advantage of this to define the TOX-dependent stage of precursor development by global transcriptome analysis of remaining progenitor cells ([Fig. 5a](#F5){ref-type="fig"}). Notably, while WT progenitor cells had a range of CD127 expression, *Tox^−/−^* cells more uniformly expressed lower amounts of this cytokine receptor ([Fig. 5a](#F5){ref-type="fig"}).

Unsupervised hierarchical clustering revealed that coordinated down-regulation of many genes was associated with the *Tox^−/−^* phenotype ([Supplementary Fig. 5](#SD1){ref-type="supplementary-material"}). This is consistent with a primary role for TOX as a transcriptional activator^[@R37]^. 713 well-annotated genes were significantly differentially expressed (\>2-fold, Q value= \<0.05) in WT and *Tox^−/−^* cells ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}).

Comparative expression of select genes is shown in [Figure 5b](#F5){ref-type="fig"}. Consistent with reporter expression ([Fig. 1d](#F1){ref-type="fig"}), *Tox* was expressed in WT precursors and acted as an internal control for *Tox^−/−^* cells. Family member *Tox2* was more moderately expressed in WT precursors compared to *Tox*, but also exhibited decreased expression in *Tox^−/−^* cells. *Tox3* expression could not be detected, while expression of *Tox4*, in general a ubiquitously expressed family member^[@R37]^, did not differ between WT and *Tox^−/−^* cells.

Genes encoding lineage markers were poorly, if at all expressed, and did not differ between WT and *Tox^−/−^* cells. Genes *Itga4* and *Itgb7,* encoding the α~4~β~7~ marker used for cell isolation, were expressed and did not differ between WT and *Tox^−/−^* cells. Both cell populations also expressed *Ptprc* and *Thy1* equivalently. Expression of *Il7r* was significantly lower in *Tox^−/−^* progenitors, consistent with cell surface expression of the encoded protein ([Fig. 5b](#F5){ref-type="fig"}), as was *Il2rg. Tox^−/−^* cells also failed to express *Bcl2* in the amounts seen in WT cells. *Il1rl1* and *IL17rb* mRNA, both expressed by mature ILC2s, were also markedly decreased in *Tox^−/−^* progenitors, as was *Eomes*. How expression of these genes in WT progenitor cells compares to that of mature ILC, however, is unknown. Thus, low expression could represent the onset of locus accessibility.

*Id2* was highly expressed in the WT progenitor population, as expected. While *Id2* was also detected in *Tox^−/−^* cells, there was an 83% reduction in average expression. Expression of genes encoding key transcriptional regulators of ILC development was also significantly decreased in *Tox^−/−^* progenitors, including *Gata3, Rorα, Rorc, Tcf7*, and *Zbtb16.* In contrast, *Gfi1* and *Nfil3* were not differentially expressed between WT and *Tox^−/−^* cells. Inducible T-cell co-stimulator (ICOS) is expressed early in ILC development and is a downstream target of PLZF^[@R38]^. ICOS was expressed on a subset of CHILP and increased upon lineage specification to ILC2p ([Fig. 5c](#F5){ref-type="fig"}). These data are consistent with CHILP containing a subpopulation of more restricted PLZF^hi^ICOS^+^ progenitors^[@R3]^. In the absence of TOX, average *Icos* expression was decreased 98% when compared to WT cells, likely indicating loss of this progenitor subpopulation.

Genes encoding other transcriptional regulators not yet reported to have a role in ILC development were also differentially expressed in WT and *Tox^−/−^* cells, including *Maf*, *Lef1 Ets1* and members of the Ikaros family, *Ikzf2* and *Ikzf3*.

A role for retinoic acid (RA) in ILC2 and ILC3 homeostasis as well as LTi maturation has recently been reported^[@R39],[@R40]^. *Rxrg* was expressed by WT cells, but was undetectable in *Tox^−/−^* progenitors. Genes encoding other RXR and RA receptor (RAR) isoforms were either not differentially expressed, or poorly expressed by both cell types. In addition, expression of the chemokine receptor gene *Ccr9*, a downstream target of RA signaling^[@R41]^, had significantly lower expression in *Tox^−/−^* progenitors. The chemokine receptor CXCR6 identifies a non-CLP, early pan-ILC progenitor population^[@R27],[@R28]^ and TOX-deficient progenitors had a significant decrease in *Cxcr6* expression.

Adult ILCs are dependent on Notch signaling for their development^[@R6],[@R18]--[@R20]^. Consistent with this, the Notch target gene *Hes1* was expressed by WT progenitors. Surprisingly, however, *Notch* genes were poorly or undetectably expressed in these cells. As ILC development may require a transient Notch signal^[@R6],[@R18]^ we considered the possibility that this might be caused by Notch downregulation. To address this, we stained CLP, α~4~β~7~^+^ progenitors, and more restricted ILC2p for Notch1 ([Fig. 5d](#F5){ref-type="fig"}). Indeed, Notch1 was more highly expressed in CLP than downstream progenitors. *Tox*^−/−^ CLP expressed Notch1 normally ([Fig. 5d](#F5){ref-type="fig"}). Despite this, *Tox*^−/−^ α~4~β~7~^+^ progenitors failed to upregulate *Hes1*, as well as the Notch target gene *Tcf7*^[@R7]^ ([Fig. 5b](#F5){ref-type="fig"}). Taken together, TOX-deficient progenitors lack key ILC transcriptional regulators necessary for their subsequent development.

*In vitro* ILC differentiation requires TOX {#S6}
-------------------------------------------

RNA-seq analysis suggested there could be poor survival of ILC progenitors in the absence of TOX, as well as failure to fully activate genes downstream of Notch signaling. ILC development can be modeled *in vitro* by culturing BM-derived CLP with OP9 stromal cells that express the DL1 Notch ligand (OP9-DL1)^[@R6]^. We took advantage of this system, which allows analysis of cell numbers as well as cell differentiation, to determine the expression and role of TOX during ILC specification. CLP were cultured with OP9-DL1 cells or, as a control, OP9 cells; the latter promoting B cell development. CLP from WT and *Tox^−/−^* animals showed similar CD127 expression ([Supplementary Fig. 6a](#SD1){ref-type="supplementary-material"}) and equivalent B cell potential ([Supplementary Fig. 6b](#SD1){ref-type="supplementary-material"}).

To assess TOX induction, CLP derived from WT or *Tox*^TOM^ animals were cultured with OP9-DL1 cells. As early as six days in culture, differentiation of CLP resulted in significant cell expansion and appearance of Lin^−^Thy-1^+^CD25^−^, Lin^−^Thy-1^+^CD25^hi^, and Lin^−^Thy-1^hi^ cell populations, with increasing expression of TOM in these cells, respectively ([Fig. 6a](#F6){ref-type="fig"}). A small subpopulation of Lin^−^Thy-1^−^CD25^−^ cells remained in culture and did not express TOM, likely representing undifferentiated CLP ([Fig. 6a](#F6){ref-type="fig"}).

To determine the effect of loss of TOX in this system, differentiation of WT and *Tox^−/−^* CLP was compared. *Tox^−/−^* CLP showed significant deficits in cell expansion ([Fig. 6b](#F6){ref-type="fig"}) and differentiation ([Fig. 6c--e](#F6){ref-type="fig"}). We also noted that Lin^−^Thy-1^hi^ cells derived from *Tox^−/−^* CLP failed to downregulate CD25 ([Fig. 6c, f](#F6){ref-type="fig"}) and upregulate ICOS ([Fig. 6f](#F6){ref-type="fig"}).

We compared the Lin^−^Thy-1^lo^CD25^+^ to Lin^−^Thy-1^hi^ transition for expression of transcriptional regulators involved in ILC development^[@R4],[@R6],[@R7],[@R21],[@R24]^. Significant upregulation of *Id2*, *Gata3*, *Rorα*, *Tcf7*, and *Zbtb16* was detected in WT Lin^−^Thy-1^hi^ cells, consistent with developmental progression of these cells to an ILC fate ([Fig. 6g](#F6){ref-type="fig"}). However, expression of *Id2*, *Gata3*, and *Rorα*, was well below that of mature WT ILC2s (used as an internal comparison for gene expression in [Fig. 6g](#F6){ref-type="fig"}). Upregulation of *Tox* in Lin^−^Thy-1^hi^ cells was consistently observed in individual experiments, although it did not reach overall statistical significance ([Fig. 6g](#F6){ref-type="fig"}). However, in conjunction with measurement of TOM expression ([Fig. 6a](#F6){ref-type="fig"}), *Tox* is induced early in these cultures with likely increased expression as cells transit to the Lin^−^Thy-1^hi^ stage.

To determine if TOX was required for establishing aspects of the ILC gene program, irrespective of poor production of Thy-1^hi^ cells, we analyzed cell populations six days after initiation of culture. *Rorα*, *Tcf7,* and *Zbtb16* were significantly decreased in *Tox^−/−^* Lin^−^Thy-1^hi^ cells relative to their WT counterparts ([Fig. 6g](#F6){ref-type="fig"}). Upregulation of *Id2* and *Gata3*, in contrast, was not significantly different in WT and *Tox*^−/−^ cells at this early stage of differentiation ([Fig. 6g](#F6){ref-type="fig"}).

To further delineate the developmental potential of TOX-deficient CLP into ILC lineages, *in vitro*-generated WT and *Tox^−/−^* Lin^−^Thy-1^hi^ cells were cultured at an equal ratio in ILC-promoting conditions. These cells differentiated into ILC1 and ILC2 lineages ([Fig. 7a, b](#F7){ref-type="fig"}) and retained Thy-1^hi^ expression. However, greater than 90% of ILC1s and ILC2s were WT derived ([Fig 7a, b](#F7){ref-type="fig"}), despite eliminating the growth and differentiation (i.e. transition to Thy-1^hi^) advantage of WT cells. Interestingly, NK1.1^−^ICOS^−^ cells that remained in these cultures showed no bias towards a WT phenotype ([Fig 7a, b](#F7){ref-type="fig"}), pointing towards a specific defect in differentiation in the absence of TOX, and not solely diminished cell growth or survival.

To assess the role of TOX in generation of functional ILC, cultures were maintained under ILC2 conditions and ICOS was used as a marker^[@R6]^. *Tox^−/−^* CLP were poor generators of Lin^−^Thy-1^hi^ cells ([Fig 7c](#F7){ref-type="fig"}). Nevertheless, re-plating equivalent numbers of mutant and WT cells at day six and then every six days onward allowed a comparative analysis at day 18. At this time point, a well-defined population of Lin*^−^*Thy-1^hi^ICOS^+^CD25^lo/neg^ cells was present in WT cultures ([Fig. 7d](#F7){ref-type="fig"}). A comparison of ICOS^−^ and ICOS^+^ WT cell populations demonstrated significant upregulation of *Id2*, *Gata3*, *Rorα*, and *Zbtb16* in the latter, now reaching levels equivalent to or exceeding that found in mature ILC2s ([Fig. 7e](#F7){ref-type="fig"}). *Nfil3*, a factor required for normal development of cNK^[@R42]^ and other ILCs^[@R25]--[@R27],[@R43]^, was also significantly upregulated in Lin^−^Thy-1^hi^ICOS^+^ WT cells ([Fig. 7e](#F7){ref-type="fig"}). In contrast, neither *Tox* nor *Tcf7* was differentially expressed between ICOS^−^ and ICOS^+^ WT cell populations ([Fig. 7e](#F7){ref-type="fig"}), consistent with an earlier induction peak ([Fig. 6g](#F6){ref-type="fig"}).

In addition to the severe differentiation deficit of mutant CLP to the Lin^−^Thy-1^hi^ stage, few ICOS^+^CD25^lo/neg^ *Tox^−/−^* cells formed in these cultures ([Fig. 7d, f, g](#F7){ref-type="fig"}). Moreover, WT cells secreted IL-5 ([Fig. 7h](#F7){ref-type="fig"}) and IL-13 ([Fig. 7i](#F7){ref-type="fig"}), presumably in response to IL-33 in the culture, confirming the development of functional ILC2s. In contrast, *Tox^−/−^* culture supernatants contained no detectable IL-5 and IL-13 ([Fig. 7h, i](#F7){ref-type="fig"}), mirroring TOX-dependence of ILC2 development observed *in vivo*.

ILC progenitors express α~4~β~7~^[@R3],[@R24]^, and we observed initial upregulation of this integrin at day six on Thy-1^hi^ cells (data not shown). At day 18, the majority of WT ICOS^+^ cells further upregulated α~4~β~7~ ([Fig. 7j](#F7){ref-type="fig"}). In contrast, *Tox^−/−^* cultures contained a low frequency of ICOS^+^ cells, and these cells failed to fully upregulate α~4~β~7~ ([Fig. 7j](#F7){ref-type="fig"}). PLZF is expressed in α~4~β~7~ ^+^ ILC progenitors that can give rise to ILC1s, ILC2s, and ILC3s and is required for development of some ILC lineages^[@R24]^. Poor upregulation of *Zbtb16* (encoding PLZF) at day six, coupled with inhibition of later development of ICOS^+^ and α~4~β~7~^hi^ cells, led us to ask whether PLZF expression would also be compromised in the absence of TOX. In WT cultures, the majority of ICOS^+^ cells were PLZF^hi^, with lower expression in ICOS^−^ cells ([Fig. 7e](#F7){ref-type="fig"}). In *Tox^−/−^* cultures, PLZF^hi^ cells fail to develop, including in the minor population of Lin^−^Thy-1^hi^ICOS^+^ cells ([Fig. 7k](#F7){ref-type="fig"}). Therefore, TOX-deficient CLP fails to develop into ILCs even in the presence of sustained Notch signaling.

DISCUSSION {#S7}
==========

The identification and characterization of ILCs has led to considerable advances in understanding the cellular mechanisms that underlie immunological responses during homeostasis and disease. Overlaps in the transcriptional networks that regulate T effector subtypes and ILCs have been reported, yet the developmental changes that specifically lead to an ILC fate have not been well established. Here, we identified an obligatory role for the transcription factor TOX in the development of ILC1, ILC2, and ILC3 lineages, due to a block in the transition of CLP to common ILC progenitors. By whole transcriptome sequencing and TOX reporter generation, we identified the post-CLP stage of ILC development in which TOX is required. Furthermore, our data offers a window into other potential regulators of the ILC lineage, including a number of transcriptional regulators not previously implicated in ILC development.

The Id2^hi^CD25^−^ subset of α~4~β~7~^+^ progenitors includes CHILP, which can give rise to all adult ILC with the exception of cNK^[@R3]^. All CHILP expressed *Tox* by reporter. A minor subset of CXCR6^+^ cells within the α~4~β~7~ progenitor population was recently reported to have *in vivo* potential to produce ILC1, ILC2, ILC3, and cNK, and to be dependent on the transcriptional regulator NFIL3^[@R27]^. NFIL3 was reported to be required for TOX induction in adult BM^[@R27]^, although other data suggest a primary role for NFIL3 in regulating Id2 in CHILP ^[@R43]^. Surprisingly, TOX-deficient but not NFIL3-deficient mice lack LTi cells required for lymph node organogenesis and thus the exact relationship between these two factors remains to be elucidated. In addition, the relationship between CHILP and CXCR6^+^ progenitors is unclear. CXCR6^+^ cells may be a small subset of CHILP, making detection of the cNK cell fate difficult to discern in this mixed population or alternatively, there could be lower expression of Id2 in CXCR6^+^ cells compared to CHILP and thus represents a distinct cell population.

Isolated *Tox^−/−^* cells were lower for cell surface CD127 expression compared to the majority of their WT counterparts and expressed less *Il7r* mRNA. The transition of fetal liver LTi precursors from RORγt^−^ to RORγt^+^ is associated with upregulation of CD127^[@R44]^. In addition, a proportion of isolated WT α~4~β~7~^+^ progenitors are CD127^lo^. Thus, we propose that *Tox^−/−^* α~4~β~7~^+^ progenitors represent a post-CLP but pre-CHILP transitional cell state, with intermediate expression of Id2 and CD127, and that these cells cannot undergo lineage specification in the absence of TOX.

Like T cells, ILCs are dependent on Notch signaling, with a transient Notch signal favoring the ILC lineage^[@R6]^. Expression of Notch gene targets *Hes1* and *Tcf1*^[@R7]^, and expression of potential downstream gene targets of TCF1, *Bcl11b* and *Gata3*,^[@R7]^ were significantly reduced in *Tox^−/−^* α~4~β~7~^+^ progenitors. Down regulation of *Notch1* mRNA is also associated with upregulation of CXCR6 on α~4~β~7~^+^ progenitors^[@R28]^. It is possible that downregulation of Notch genes during early ILC development ensures a transient Notch signal. Moreover, these data may indicate that one primary deficit in *Tox^−/−^* cells may be an inability to activate downstream gene targets of Notch signaling. Interestingly, binding of TOX to the *HES1* gene has been detected in HEK-293T cells ^[@R45]^.

*Maf*, a transcription factor that plays a critical role in the differentiation of various T helper cell subsets^[@R46]^, was differentially expressed in WT and *Tox^−/−^* cells and possibly represents a new example of overlap in the transcriptional landscape of ILC and T-helper cell lineages. In the absence of TOX, expression of *Rxrg* and the RA target gene *Ccr9* was also significantly reduced, pointing to the potential for modulation of ILC development by RA signaling in ILC progenitor populations, as has been reported for mature ILC subtypes^[@R39],[@R47]^.

The small intestine contains a mix of fetal-derived LTi-like cells that express CCR6 and a heterogeneous mix of postnatal ILC^[@R36]^. Here, the frequencies of major populations of small intestine LP ILC3 were comparable between WT and *Tox^−/−^* mice. These data may suggest a TOX-independent pathway of gut-resident ILC3 development. LP contain CLP-like cells that can give rise to NK and RORγt^+^ cells in culture^[@R28]^, and thus the relative contribution of BM progenitors to LP ILC3 development is not clear. Alternatively, it is possible that the gut microenvironment is particularly conducive to expansion of any ILC3 that may form, even in small numbers. A proportion of CCR6^−^T-bet^+^ ILC3 in LP are proliferative^[@R36]^, and in general, small intestine LP ILC have a transcriptome associated with activated cells when compared to ILC in other locations^[@R47]^. Post-natal proliferation of LP ILC3 could be particularly pronounced in *Tox^−/−^* mice, which have a block in CD4^+^ T cell, including T regulatory cell, development^[@R31]^. In support of a disturbed gut microenvironment in these animals, we can detect Lin^+^CD4^+^RORγt^+^ cells in *Tox^−/−^* mice despite the thymic block, and a high frequency of other Lin^+^RORγt^+^ cells. This potential inflammatory environment could influence homeostasis of ILC3 populations. A definitive molecular dissection of small intestine ILC3 development awaits further experimentation.

Based on these data, we propose the following events regarding the role of TOX in ILC development. Notch signaling in CLP leads to upregulation of α~4~β~7~ and early factors TOX and Id2. TOX may be required for translation of Notch signals to downstream gene expression, including induction of *Tcf7* and *Hes1.* Relatively rapid downregulation of Notch genes at a TOX^lo^Id2^lo^CD127^lo^ transitional stage may extinguish continued Notch signaling, promoting an ILC rather than a T cell fate. Loss of TOX at this early stage results in a cascading failure to initiate programs of cell survival and differentiation required for continued ILC lineage specification through CXCR6^+^, CHILP, and PLZF^hi^ progenitor stages, and ultimately, failure of ILC lineage commitment.

METHODS {#S8}
=======

Mice {#S9}
----

All mice were bred at the Cedars-Sinai Medical Center and kept under specific pathogen-free conditions. Mice used for experiments were between 6--14 weeks of age, of either sex. *Tox^TOM^* reporter mice were generated by insertion of tandem dimer Tomato (TOM) coding sequence lacking a transcriptional stop at the start ATG of Tox exon 1 by standard methodology (inGenious Targeting Laboratory). A neomycin cassette within FRT sites was removed by breeding with FLPase mice. FLPase negative mice were selected in a subsequent generation, and heterozygous reporter mice maintained on a C57BL6/J background for experiments. *Tox ^−/−^* mice were generated as described previously, and maintained by *Tox ^−/−^* x *Tox^+/−^* breeding^[@R31]^. B6.129S (Cg)-*Id2^tm2.1Blh^*/ZhuJ *Id2^GFP^* reporter mice were obtained from The Jackson Laboratory and bred to *Tox^TOM^* reporter animals to generate a double reporter strain. Mice heterozygous for both reporters were used in experiments. NOD.Cg-*Prkdc^scid^ Il2rg^tm1Wjl^*/SzJ (NSG) mice were obtained commercially (The Jackson Laboratory). Mice were selected for experimental groups based only on genotype within the age range indicated above. Within experiments, animals of each genotype were age-matched as closely as possible within constraints of availability. No blinding or specific randomization protocol was used. All animal procedures were performed in accordance with protocols approved by the CSMC Institutional Animal Care and Use Committee.

Isolation of lymphocytes from BM, lung and lamina propria {#S10}
---------------------------------------------------------

Whole lung was removed following a 5 ml injection of PBS into the right ventricle of the heart. Lungs were minced and digested in HBSS containing 1 mg/ml Liberase with 10 U/ml DNase I (Roche Diagnostics). Cells were filtered using a 70 μm cell strainer and red blood cells lysed. For CD27 labeling, 0.5 mg/ml collagenase type VIII (Sigma) was used. For IL-33 induced ILC2 expansion *in vivo*, animals were injected intraperitoneally once daily with 500 ng IL-33 (BioLegend) or with PBS for four days.

Colons were removed, opened longitudinally and washed in PBS to remove fecal content. Intestines were cut into two centimeter segments, transferred into HBSS supplemented with 2% FBS and 2 mM EDTA, and shaken for 15 min at 37°C. This step was repeated twice in order to remove epithelial cells and fat tissue. The remaining intestinal tissue was washed, cut in small segments and incubated in digestion media consisting of RPMI 1640, 2% FBS, 0.5 mg/ml collagenase type VIII, 5 U/ml DNase, 100 IU/ml penicillin and 100 μg/ml streptomycin for 40 min at 37°C by gentle shaking. Digested suspensions were filtered, washed in PBS and cells were collected for analysis.

RNA-seq and data analysis {#S11}
-------------------------

We performed a customized low input RNA-seq protocol to allow whole transcriptome measurements with as few as 250 cells. Isolated bone marrow cell populations were sorted into a 96-well plate containing lysis buffer (SMARTer® Ultra^™^ Low Input RNA v3 kit, Takara) for sequencing which was also used for constructing cDNA libraries per manufacturer's instructions. The protocol for the Ion Torrent Proton was modified by enzymatically fragmenting the resulting double-stranded cDNA libraries and ligating sequencing adapters from the Ion Xpress^™^ Plus Fragment Library Kit (Life Technologies). cDNA libraries were amplified onto Ion Sphere Particles using Ion PI^™^ template OT2 200 Kit v3 (Life Technologies) and then sequenced on the Ion Proton^™^. Samples were sequenced with the Ion PI^™^ Sequencing 200 v3 kit (Life Technologies) to a depth of 12 to 25 million reads with less than 2.5% of reads coming from ribosomal RNA and over 90% of reads mapping to the mouse genome. The raw reads were filtered and trimmed by FASTX toolkit (<http://hannonlab.cshl.edu/fastx_toolkit/>) then aligned to mouse reference genome (mm10) using TMAP with mouse reference Gencode version 19 reference genome annotation (<http://www.gencodegenes.org>). FPKM (fragment per kilobase of gene per million reads sequenced) values were calculated for 23,847 genes using Cufflinks 2.0.8. Poorly measured raw FPKM values less than 1 were increased to a floor threshold of 1. Raw FPKM values were then log~2~ transformed. Genes with an average of 1 or less in addition to miRNAs and SNORDs where removed from further analysis. Unsupervised analysis was performed by filtering FPKM values for any three of eight samples that demonstrated at least five-fold greater expression than any other sample. For visualization of coordinated gene expression in samples, we performed 2-way hierarchical clustering with samples and genes. Genes were mean centered and dendrograms were calculated using hclust and plotted using heatmap.2 (v2.12) in gplots (v 2.14.2) in R (v 3.0.2). A two-tailed *t*-test was used to assess the significance of gene expression differences and then corrected for multiple hypotheses by calculating the q value using the Benjamini and Hochberg method. Data from well-annotated genes that had significant gene expression differences with a false discovery rate below 5% (defined as a q value \< 0.05) are presented ([Supplementary Table 2](#SD3){ref-type="supplementary-material"}). Data were deposited in Gene Expression Omnibus at NCBI (<http://www.ncbi.nlm.nih.gov/geo/>) and can be obtained using accession code GSE65850.

Generation of bone marrow chimeras {#S12}
----------------------------------

CLPs were sorted from *Tox^−/−^* (Thy-1.2^+^, CD45.2^+^) and B6.PL-Thy1a/CyJ (Thy-1.1^+^, CD45.2^+^) animals and mixed at a 1:1 ratio using 3.0 × 10^4^ cells per genotype. NSG (CD45.1^+^) mice were reconstituted with 6.0 × 10^4^ CLPs by injection into the tail vein. Mice were analyzed two weeks later.

*In vitro* differentiation assay {#S13}
--------------------------------

Whole BM was extracted as described above. CLPs were isolated by cell sorting directly into complete DMEM containing IL-7 (20 ng/ml) and IL-33 (20 ng/ml) (Biolegend) for ILC2 conditions or IL-7 (10 ng/ml), SCF (50 ng/ml) (R&D Systems) and Flt3L (5 ng/ml) (R&D Systems) for B cell conditions. Following isolation, cells were immediately transferred to mitomycin c treated (Sigma) confluent OP9-DL1 (ILC2 conditions) or OP9 (B-cell conditions) at a density of 3000--7500 cells/well in 48 well plates. Cells were passaged and added to fresh OP9 or OP9-DL1 monolayers every six days. For competitive *in vitro* ILC differentiation, BM was extracted as described above from *Tox^−/−^* and B6.SJL-*Ptprc^a^ Pepc^b^*/BoyJ (Ly5.2) mice. CLPs were isolated by cell sorting directly into complete DMEM containing IL-7 (20 ng/ml) and immediately transferred to mitomycin c treated, confluent OP9-DL1 at a density of 8000 cells/well in 48 well plates. Six days later, Lin^−^Thy-1^hi^ cells were sorted directly into complete DMEM containing IL-7 (20 ng/ml) and SCF (50 ng/ml), were mixed at a 1:1, WT (CD45.2^+^):*Tox^−/−^* (CD45.2^−^) ratio, and immediately transferred to confluent OP9-DL1 at a density of 8000 cells/well in a 48 well plate. Cells were analyzed 6 days later.

IL-13 and IL-5 determination {#S14}
----------------------------

Whole culture medium from *in vitro* generated ILC2 was collected at day 18 and analyzed for IL-13 and IL-5 by ELISA per manufacturer's instructions (eBioscience).

Antibodies and flow cytometry {#S15}
-----------------------------

All antibodies used for flow cytometry were purchased from eBioscience, Biolegend or BD Biosciences and are listed in [Supplementary Table 3](#SD2){ref-type="supplementary-material"} with clone designations in parentheses. Lineage markers used for each population analyzed can be found in [Supplementary Table 3](#SD2){ref-type="supplementary-material"}. RORγt, GATA-3, T-bet, Eomes and PLZF intracellular staining was conducted using the FoxP3 staining kit as per manufacturer's instructions (eBioscience). All samples were pre-incubated with anti-CD16/32 (93) to block FcR. Cells were analyzed using a LSRII and isolated using a FACS Aria III (BD Biosciences). CD1d (PBS57) was generously provided by the NIH tetramer core facility.

qRT-PCR {#S16}
-------

All data was normalized to *Hprt* and presented relative to expression determined from IL-33 expanded lung ILC2 cell mRNA. cDNA was generated using Superscript VILO (Life Technologies) and amplified using QuantiTect SYBR green. All primer sets were purchased from QIAGEN (QuantiTect), except for *Tox* and *Rorα* primers, which were as follows: *Tox* F: 5′-TGCCTGGACCCCTACTATTG and Tox R: 5′-CTGGCTGGCACATAGTCCTG. *Rora* F: 5′-TCTCCCTGCGCTCTCCGCAC and R: 5′-TCCACAGATCTTGCATGGA^[@R48]^.

Statistics {#S17}
----------

Means, standard deviations, and the probability (P) associated with a Student's *t*-test using a two-tailed distribution of equal variance are shown in some figures. P values of \<0.05 were considered to represent means with a statistically significant difference. Statistical analysis was performed on groups with similar variance and limited variance was observed within sample groups. Sample or experiment sizes were determined empirically for sufficient statistical power. No statistical tests were used to predetermine the size of experiments and no samples were excluded specifically from analysis.
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![TOX is expressed in ILC progenitors and mature ILC lineages. (**a**) Deletion of the neomycin cassette was accomplished by breeding to FLPase recombinase expressing mice. FLPase was removed in subsequent breeding to generate *Tox*^TOM^ reporter mice. Restriction enzyme sites (P=PstI, S=StuI, R=EcoRI) are shown in surrounding non-coding sequences only. *Tox^TOM^* mice were also bred to *Id2*^GFP^ mice to generate a dual reporter strain used in many experiments. (**b**) Flow cytometry of Lin^−^CD122^+^ cells from BM and spleen for TOM and GFP in NKp, *i*NK, and mNK populations (*n*=3). Numbers refer to frequency of gated population here and in subsequent figures. (**c**) Expression of TOM and GFP in BM CLP reporter mice as indicated (*n*=3). (**d**) TOM and GFP expression in BM Lin^−^α~4~β~7~^+^CD127^+^ cells subgated by CD25 (*n*=3). (**e**) Lung ILC2s from WT and *Tox^TOM^Id2^GFP^* mice were analyzed for reporter expression (*n*=3). (**f**) Expression of *Tox* and *Gata3* by qRT-PCR in IL-33-expanded ILC2s, *in vitro* generated T~H~2 cells, and CD19^+^B220^+^ splenic B cells (*n*=2--3). (**g, h**) Expression of TOM in WT and *Tox^TOM^* lamina propria cells gated as shown (*n*=3). (**i, j**) Expression of TOM in splenic subpopulations (n=3) as in (**g**). *\*P* \<0.05, NS= non-significant, *P* \>0.05 (Student's *t*-test). Data (± s.d.) are representative of three (**b--e, g--j**) or two (**f**) independent experiments.](nihms676873f1){#F1}

![TOX is required for the development of ILC progenitors. (**a**) Staining for BM CLP from WT and *Tox^−/−^* mice (*n*=6). (**b, c**) Compiled data of the frequency (**b**) and number (**c**) of Flt3^+^Sca-1^int^ cells within the Lin^−^CD45^+^ cell population from WT and *Tox^−/−^* BM. (**d**) Lin^−^α~4~β~7~^+^CD127^+^ cells from BM of WT and *Tox^−/−^* animals (*n*=3). (**e**) Gated Lin^−^α~4~β~7~^+^CD127^+^ cells from WT and *Tox^−/−^* animals were analyzed for CD25. Shown is the frequency of CD25^−^ cells (*n*=3). (**f**) Number of Lin^−^α~4~β~7~^+^CD127^+^CD25^−^ cells in WT and *Tox^−/−^* animals. (**g**) Lin^−^CD45^+^NK1.1^+^NKp46^+^ cells were analyzed for cNK (CD27^+^CD127^−^) and ILC1s (CD27^+^CD127^+^) from WT and *Tox^−/−^* mice in BM. The lack of Lin^−^CD45^+^NK1.1^+^NKp46^+^ cells from *Tox^−/−^* mice precluded any additional subset analysis. (**h, i**) Compiled data of the frequency (**h**) and number (**i**) of NK1.1^+^NKp46^+^ cells within the Lin^−^CD45^+^ cell population from BM. (**j**) Staining for BM ILC2p from WT and *Tox^−/−^* mice. (**k, l**) Compiled frequency (**k**) and absolute numbers (**l**) of BM ILC2p. *\*\*P* \<0.01, *\*\*\*P* \<0.001, NS= non-significant, *P* \>0.05 (Student's *t*-test). Symbols (**b, c, f, h, I, k, l**) represent individual mice analyzed independently; horizontal lines denote the mean.](nihms676873f2){#F2}

![TOX is required for the development of mature ILCs. (**a**) Comparison of lung NK1.1^+^NKp46^+^ cells within the Lin^−^CD45^+^ population from WT and *Tox^−/−^* mice (*n*=3). (**b**) Intracellular staining of WT, lung Lin^−^CD45^+^NK1.1^+^NKp46^+^ population as shown in (**a**) including cNK and ILC1s (*n*=3). (**c, d**) Compiled frequency (**c**) and absolute numbers (**d**) of lung NK1.1^+^NKp46^+^ population. (**e, g**) Colon (**e**) and small intestine (**g**) lamina propria NK1.1^+^NKp46^+^ cells from WT and *Tox^−/−^* mice (*n*=3). (**f, h**) Frequency of colon (**f**) and small intestine (**h**) NK1.1^+^NKp46^+^ population. (**i**) Comparison of lung ILC2s from WT and *Tox^−/−^* mice (*n*=10). (**j, k**) Compiled frequency (**j**) and absolute numbers (**k**) of lung ILC2s. (**l**) Staining for lung ILC2 in WT and *Tox^−/−^* animals treated with IL-33 or PBS (*n*=3--5). (**m, n**) Frequency (**m**) and absolute numbers (**n**) of ILC2s from WT and *Tox^−/−^* lung, treated as indicated. (**o**) Comparison of ST2 expression on IL-33-expanded lung Lin^−^CD45^+^Thy-1^+^ cells isolated from WT or *Tox^−/−^* mice (*n*=3--5). (**p**) Comparison of splenic Lin^−^CD45^+^CD127^+^c-Kit^+^ cells from WT and *Tox^−/−^* mice gated as shown (*n*=4). (**q**) Absolute numbers of total spleen Lin^−^CD45^+^CD127^+^c-Kit^+^. (**r**) Absolute numbers of RORγt^+^CD4^−^ and CD4^+^ cells as gated in (**p**). *\*P* \<0.05, *\*\*P* \<0.01, *\*\*\*P* \<0.001, NS= non-significant, *P* \>0.05 (Student's *t*-test). Symbols (**c, d, f, h, j, k, m, n, q, r**) represent individual mice analyzed independently; horizontal lines denote the mean.](nihms676873f3){#F3}

![TOX regulates the development of ILCs by a cell-intrinsic mechanism. (**a--d**) Donor-derived (CD45.2^+^) cells in (**a**) BM (*n*=4), (**b, c**) lung (*n*=3), and (**d**) spleen (*n*=3) were analyzed for allelic markers for WT (Thy-1.1^+^) or *Tox^−/−^* (Thy-1.2^+^) genotypes. (**e**) Ratio of *Tox*^−/−^ to WT cells in the indicated populations. *\*\*\*P* \<0.001 (Student's *t*-test). Data (± s.d.) are compiled from four (**a**) or three (**b, c, d**) experiments, pooling two animals per experiment.](nihms676873f4){#F4}

![Whole transcriptome analysis of *Tox^−/−^* α~4~β~7~^+^ progenitors reveals a block in induction of the ILC gene program. (**a**) Gating strategy used for isolation of Lin^−^CD127^+^α~4~β~7~^+^CD25^−^Flt3^−^ cells from WT and *Tox^−/−^* mice (*n*=4). (**b**) Heat map of select gene expression. PE, poorly expressed (average FPKM of both genotypes ≤ 2), NS, not significant (Q value ≥ 0.05) (Student's *t*-test, Benjamini and Hochberg correction for multiple tests). (**c**) Expression of ICOS or isotype control (filled histograms) in CHILP from *Id2^GFP^* reporter mice (*n*=2). (**d**) WT progenitor cells as gated in (**a**) were compared to ILC2p and CLP for Notch1 surface expression (*n*=2). (**e**) CLP from WT and *Tox^−/−^*mice were analyzed for Notch1 (*n*=2). Data are compiled from four (**b**) independent experiments, pooling 2--3 animals per experiment per genotype.](nihms676873f5){#F5}

![*In vitro* ILC specification is blocked early in the absence of TOX. (**a**) Subpopulations at day six of Lin^−^ cells subgated on Thy-1 and CD25 were analyzed for TOM expression (*n*=3). (**b**) Calculated fold expansion over number of input WT or *Tox^−/−^* CLP at day six. (**c**) Differentiation of WT and *Tox^−/−^* CLP at day six was assessed by expression of Thy-1 and CD25 (*n*=6). (**d, e**) Frequency (**d**) and number (**e**) of Lin^−^Thy-1^hi^ cells (% of Lin^−^) gated as in (**c**). (**f**) Lin^−^Thy-1^hi^CD25^−^ICOS^+^ WT and *Tox^−/−^* cells at day six in culture (*n*=6). (**g**) Lin^−^Thy-1^lo^ and Lin^−^Thy-1^hi^ cell populations were isolated by cell sorting and expression of indicated genes was determined by qRT-PCR. Data was normalized to *Hprt* expression and presented relative to *in vivo*, IL-33-expanded ILC2s. *\*P* \<0.05, *\*\*P* \<0.01, *\*\*\*P* \<0.001, NS= non-significant, *P* \>0.05 (Student's *t*-test). Symbols (**b, d, e**) represent individual mice analyzed independently; horizontal lines denote the mean. Data (± s.d.) are compiled from four mice (**g**), using CLP pooled from two animals per experiment.](nihms676873f6){#F6}

![In the absence of TOX, there is a cell-intrinsic differentiation defect in the generation of ILC1s and functional ILC2s. (**a**) Frequency of WT (CD45.2^+^) and *Tox^−/−^* (CD45.2^−^) *in vitro* differentiated non-ILCs (ICOS^−^NK1.1^−^), ILC2s (ICOS^+^NK1.1^−^T-bet^−^GATA-3^+^) and ILC1s (ICOS^+^NK1.1^+^T-bet^+^GATA-3^−^) (*n*=4). (**b**) Transcription factor staining for WT ILC1s and ILC2s (*n*=4). (**c**) WT to *Tox^−/−^* ratio of populations in (**a**). (**d**) CLPs were isolated from WT and *Tox^−/−^* BM, cultured for six, 12, or 18 days, and numbers of Lin^−^Thy-1^hi^ cells determined. Data are calculated based on input number of CLP. (**e**) Analysis of day 18 cultures as shown (*n*=7). (**f**) Gene expression in day 18 Lin^−^Thy-1^hi^ICOS^−^ or ICOS^+^ cells, determined as in [Fig. 6](#F6){ref-type="fig"}. (**g, h**) Frequency (% of Lin^−^Thy-1^hi^) (**g**) and cell numbers (**h**) of WT culture-generated ICOS^+^ cells gated as in (**e**). Cell numbers are expressed as total cells recovered at day 18 per 5,000 cells plated at day 12. (**i, j**) Quantification of secreted IL-5 (**i**) or IL-13 (**j**) from *in vitro* differentiated CLP. (**k, l**) Expression of α~4~β~7~ (**k**) and PLZF (**l**) on Lin^−^Thy-1^hi^ cells. Histograms display results from isotype control, ICOS^−^ and ICOS^+^ cells (*n*=3). *\*P* \<0.05, *\*\*P* \<0.01, *\*\*\*P* \<0.001, NS= non-significant, *P* \>0.05 (Student's *t*-test). Symbols (**c, g, h, I, j**) represent individual mice analyzed independently; horizontal lines denote the mean. Data are compiled from seven (**d**) or three (**f**) independent experiments using two animals pooled per experiment.](nihms676873f7){#F7}
